z-logo
open-access-imgOpen Access
In Vitro Enhanced Sensitivity to Cisplatin in D67Y BRCA1 RING Domain Protein
Author(s) -
Apichart Atipairin,
Adisorn Ratanaphan
Publication year - 2011
Publication title -
breast cancer basic and clinical research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.741
H-Index - 23
ISSN - 1178-2234
DOI - 10.4137/bcbcr.s8184
Subject(s) - ubiquitin ligase , dna damage , dna repair , cisplatin , ubiquitin , ring finger , cancer research , biology , microbiology and biotechnology , missense mutation , ring finger domain , ddb1 , dna ligase , mutation , chemistry , dna , genetics , transcription factor , zinc finger , gene , chemotherapy
BRCA1 is a tumor suppressor protein involved in maintaining genomic integrity through multiple functions in DNA damage repair, transcriptional regulation, cell cycle checkpoint, and protein ubiquitination. The BRCA1-BARD1 RING complex has an E3 ubiquitin ligase function that plays essential roles in response to DNA damage repair. BRCA1-associated cancers have been shown to confer a hypersensitivity to chemotherapeutic agents. Here, we have studied the functional consequence of the in vitro E3 ubiquitin ligase activity and cisplatin sensitivity of the missense mutation D67Y BRCA1 RING domain. The D67Y BRCA1 RING domain protein exhibited the reduced ubiquitination function, and was more susceptible to the drug than the D67E or wild-type BRCA1 RING domain protein. This evidence emphasized the potential of using the BRCA1 dysfunction as an important determinant of chemotherapy responses in breast cancer.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom